American Association of Individual Investors4d
Which Is a Better Investment, Catalyst Pharmaceuticals, Inc. or CRISPR Therapeutics AG Stock?
Learn more about whether Catalyst Pharmaceuticals, Inc. or CRISPR Therapeutics AG is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
Neutral On Metagenomi's Promising Yet Highly Speculative Gene Editing Potential
Financial writer discusses MGX's gene editing technology, cash runway, and lack of clinical data for potential future ...
Hosted on MSN5d
Intellia Stock Dips After Morgan Stanley Downgrade, Retail Sentiment Weakens
Intellia Therapeutics, Inc. shares declined over 5% on Monday morning after Morgan Stanley downgraded the stock to ‘Equal ...
Escaping the endosome: BEND lipids improve LNP mRNA delivery and gene editing
Every time a shuttle docks with the International Space Station (ISS), a delicate dance unfolds between the shuttle's docking ...
Viral protein Nef enables a step toward off-the-shelf CAR T cell therapy for cancer
CAR T cell therapy is one of the most promising new cancer treatments to emerge in recent years. It involves removing a ...
American Association of Individual Investors3d
Which Is a Better Investment, Natera, Inc. or Vertex Pharmaceuticals Incorporated Stock?
Learn more about whether Natera, Inc. or Vertex Pharmaceuticals Incorporated is a better investment based on AAII's A+ ...
Nature5d
Metabolic engineering articles from across Nature Portfolio
It can involve the optimization of existing biochemical pathways or the introduction of pathway components ... Applying the CRISPR-Cas9 system to edit high GC content genomes has been challenging ...
Hosted on MSN1d
Research Paves Way for Off-the-Shelf CAR T Cells for Cancer Treatment
CAR T cell therapy is one of the most promising new cancer treatments to emerge in recent years. It involves removing a ...